VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

LLMC 2020 | MM: Are anti-BCMA immunotherapies ready for the frontline?

Adriana Rossi, MD, Weill Cornell Medical College, New York City, NY, discusses on B-cell maturation (BCMA) targeted therapies in the treatment of multiple myeloma (MM). Dr Rossi highlights the status and roles of chimeric antigen receptor (CAR) T-cell therapies, bispecific T-cell engagers (BiTEs) and antibody-drug conjugates (ADCs). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

Consulting for Amgen, BMS, Janssen

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter